Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2024-06-29 Regulatory Filings
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
Form 144- NOTICE OF PROPOSED SALE OF SECURITIES-GeneDx Holdings
Regulatory Filings Classification · 95% confidence The document explicitly identifies itself as "FORM 144" and states its purpose is a "NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933." Form 144 filings relate to the resale of restricted or control securities. This type of filing does not directly correspond to the provided definitions (10-K, ER, IR, etc.). Since it is a specific regulatory filing concerning securities transactions that doesn't fit the other categories, it falls best under the general regulatory filing category, RNS (Regulatory Filings), as it is a mandatory SEC filing related to insider/control transactions, serving as a catch-all for specific SEC forms not otherwise listed.
2024-06-29 English
Form 144- NOTICE OF PROPOSED SALE OF SECURITIES-GeneDx Holdings
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *Form 144 GeneDx: ���� ����� ��"�.*' and references a PDF file. Form 144 typically relates to the proposed sale of restricted securities, which often involves insider transactions or significant share transfers, but the document itself is an announcement *about* an attached filing (Form 144). Since the text is short (1778 chars) and serves primarily to announce the availability of an attached document, it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of Form 144 (related to securities sales/insider activity), it is a specific regulatory filing. However, following the 'MENU VS MEAL' rule, since this document is merely announcing the attached Form 144 PDF rather than being the full Form 144 content itself, RPA or RNS is appropriate. Since 'Form 144' is a specific regulatory filing type, and this is an announcement of that filing, RNS (Regulatory Filings - general fallback for specific regulatory announcements not covered elsewhere) is the most appropriate general classification, although RPA is also plausible if the focus is purely on the announcement mechanism. Given the context of SEC/ISA filings, RNS is often used for these types of immediate regulatory disclosures.
2024-06-29 English
OPKO Health to Participate in the Jefferies Global Healthcare Conference.
Regulatory Filings Classification · 100% confidence The document is a very short press release (1232 characters) announcing that OPKO Health's management will be participating in the Jefferies Global Healthcare Conference, including details about a fireside discussion and investor meetings. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing like a DVA or DIRS. It is an announcement regarding management's schedule for investor engagement, which often falls under general investor relations communications. Since there is no specific category for 'Conference Participation Announcement,' and it is not a transcript (CT), presentation (IP), or earnings release (ER), the most appropriate general category for investor-facing news that doesn't fit elsewhere is Regulatory Filings (RNS), as it is a standard press release format used for broad dissemination of non-material, yet relevant, corporate updates.
2024-06-01 English
OPKO Health to Participate in the Jefferies Global Healthcare Conference.
Report Publication Announcement Classification · 98% confidence The document is a very short filing (1855 characters) originating from the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The key phrase is "Attached hereto is a report on *OPKO Health to Participate in the Jefferies Global Healthcare Conference.*". This structure—a brief announcement stating that a specific report or press release is attached or published—fits the definition of a Report Publication Announcement (RPA). It is not the full presentation (IP) or the conference transcript (CT), but rather the notice that the participation/event information has been released. Since it announces the publication of external information, RPA is the most appropriate classification over the general fallback RNS.
2024-06-01 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET A
Director's Dealing Classification · 99% confidence The document explicitly displays "FORM 4" at the top and is titled "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". This form is used under Section 16 of the Securities Exchange Act of 1934 to report insider transactions (director's dealing). While the provided definitions do not have a specific code for Form 4, the content directly relates to personal share transactions by company directors and executives, which aligns perfectly with the definition for Director's Dealing (DIRS).
2024-05-24 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET A
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The content explicitly states it concerns an 'Interested party transaction' and mentions an attached file named '20240524Form4_isa.pdf'. This structure—a brief announcement referencing an attached, specific report—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since 'Interested party transaction' is a specific type of corporate action, and the document is short (1770 chars) and serves primarily to announce the availability of the detailed report, RPA is a strong candidate. However, given the context of regulatory filings concerning specific transactions (like insider dealings or related party transactions), and the lack of a specific code for 'Interested Party Transaction' among the provided definitions, we must choose the best fit. Director's Dealing (DIRS) is for director trades, which is different. Since this is a formal regulatory disclosure announcing a specific report about a transaction, and it is not a full financial report (10-K, IR) or a management discussion (MDA), it falls under the general regulatory announcement category. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for a specific regulatory disclosure that doesn't match the other specialized codes, although RPA is also plausible if the focus is purely on the announcement mechanism. Since it is a formal regulatory report submission (Regulation 4 of the Securities Regulations), RNS is the safest classification for a non-standard, specific regulatory disclosure.
2024-05-24 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.